Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A
January 25, 202123 min read4651 words
Published: January 25, 2021  |  23 min read4651 words
SARS-CoV-2 viral proteins interact with the eukaryotic translation machinery and inhibitors of translation have potent antiviral effects. Here we report that the drug plitidepsin (aplidin), which has limited clinical approval, possesses antiviral activity (IC90 = 0.88 nM) 27.5-fo...
Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A Read more

No article scores yet.

There are no critic or public scores for this article yet.
critic reviews: 0
public reviews: 0
No reviews
img-trusted
100%
critic score
6 reviews
img-trusted
89%
public score
19 reviews
img-contested
N/A
critic score
0 reviews
img-contested
N/A
public score
0 reviews
img-contested
N/A
critic score
0 reviews
img-contested
N/A
public score
0 reviews
img-contested
N/A
critic score
0 reviews
img-contested
N/A
public score
0 reviews
img-contested
N/A
critic score
0 reviews
img-contested
N/A
public score
0 reviews
img-contested
N/A
critic score
0 reviews
img-contested
N/A
public score
0 reviews

CRITIC REVIEWS

There don't seem to be any reviews yet.

PUBLIC REVIEWS

There don't seem to be any reviews yet.